Challenges
Economic Losses:

The COVID-19 pandemic has caused significant economic losses exceeding 20 trillion USD globally.

Vaccine Hesitancy:

Despite the introduction of mRNA vaccines, vaccine hesitancy among the public continues to persist.

Evolving virus:

The threat posed by both the original and new variants of the virus continuously creates health concerns.


Opportunities
siRNA Innovation:

The FDA in the United States has approved several drugs for treating COVID-19, including antiviral medications, immune modulators, and renal replacement therapies.

IG-001, developed by Intelligene, is an siRNA drug that uses gene coding to combat the virus. We anticipate that IG-001 will provide precise targeted therapy for both known and potentially unknown variants.


IG-002

siRNA-based drug for universal flu treatment


Challenges
High Incidence and Severity:

Flu (Influenza) continues to be a significant public health challenge with an estimated 1 billion cases worldwide each year, including 3 to 5 million severe cases and hundreds of thousands of related respiratory deaths.

Emerging Pandemic Risk:

Recent lab tests with bird flu strains show that these viruses keep changing and can be a big health risk when they spread from animals to people. This warns us about possible big disease outbreaks or pandemics.


Opportunities
Advanced Drug Development:

IG-002 offers an opportunity for advanced gene therapy by targeting a conserved region in the virus' evolution, potentially addressing various flu strains.

Comprehensive and Precise Solution:

We expect IG-002 offer a more comprehensive and accurate nucleic acid therapeutic drugs with RNAi technology targeting specific genes and regions.